Aura Biosciences, Inc.
AURA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.50 | 3.00 | -0.22 | -0.26 |
| FCF Yield | -19.86% | -18.39% | -17.72% | -6.96% |
| EV / EBITDA | -4.62 | -3.94 | -3.61 | -10.11 |
| Quality | ||||
| ROIC | -56.37% | -34.70% | -27.13% | -22.36% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.92 | 0.84 | 0.93 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -25.56% | -15.91% | -61.27% | -37.63% |
| Safety | ||||
| Net Debt / EBITDA | 0.15 | 0.26 | 1.70 | 4.30 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -2,711.54 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -687.62 | -503.67 | -905.83 | -1,049.54 |